Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.88 and traded as low as $0.69. Vaxart shares last traded at $0.73, with a volume of 2,154,944 shares changing hands.

Wall Street Analyst Weigh In

Separately, B. Riley upgraded shares of Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Wednesday, January 31st.

Vaxart Stock Performance

The company has a market capitalization of $128.90 million, a P/E ratio of -1.26 and a beta of 0.72. The firm’s fifty day moving average is $1.07 and its 200 day moving average is $0.88.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. The company had revenue of $3.25 million for the quarter, compared to the consensus estimate of $0.45 million. Vaxart had a negative net margin of 1,117.56% and a negative return on equity of 108.45%. On average, analysts forecast that Vaxart, Inc. will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Vaxart

Hedge funds have recently added to or reduced their stakes in the stock. Kingswood Wealth Advisors LLC bought a new position in Vaxart in the 1st quarter worth about $32,000. PFG Investments LLC bought a new position in Vaxart in the 1st quarter worth about $38,000. Beacon Capital Management LLC grew its stake in Vaxart by 369.9% in the 4th quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 40,000 shares in the last quarter. Finally, AE Wealth Management LLC grew its stake in Vaxart by 180.7% in the 3rd quarter. AE Wealth Management LLC now owns 62,113 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 39,987 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.